Cancer Related
CYFRA 21.1 Blood Test
£90.00
Monitor oncology treatment and epithelial tumour activity with a private Cytokeratin-19 Fragments (CYFRA 21.1) blood test at Medical Diagnosis Victoria (MDX Victoria) in London.
This test measures the level of cytokeratin-19 fragments circulating in your bloodstream. Because this structural protein is released by specific epithelial cells, evaluating this biomarker is highly effective for monitoring non-small cell lung cancer, supporting the diagnosis of urothelial carcinoma, and assessing your overall response to treatment in selected malignancies.
With a 5-day turnaround, this targeted screening provides the reliable clinical data your doctor needs to track disease progression and guide effective oncological care.
Oncology & Tumour Marker Surveillance
Private CYFRA 21.1 Blood Test in London
Cytokeratin-19 Fragments (CYFRA 21.1) is a specialized tumour biomarker primarily used in the clinical management of specific epithelial malignancies. At Medical Diagnosis Victoria (MDX Victoria), we provide a private CYFRA 21.1 blood test to support the monitoring of non-small cell lung cancer (NSCLC), investigate urothelial (bladder) carcinomas, and track objective oncology treatment outcomes. Our clinical practitioners in central London deliver attentive, confidential care with comprehensive laboratory results available within 5 days.
📊 Test Specifications
Clinic Testing Fee
£90.00
+ £24.00 Phlebotomy Fee
Sample RequiredBlood Sample
Turnaround Time5 Days Processing
PreparationNo special instructions
StatusReferral Laboratory Analysis
Diagnostic Focus
What is the CYFRA 21.1 Test?
Cytokeratins are structural proteins that form the internal framework (cytoskeleton) of epithelial cells, which line the surfaces and cavities of the body. When epithelial tumour cells multiply rapidly and subsequently undergo cell death (apoptosis), they release soluble fragments of Cytokeratin-19 into the bloodstream. Measuring the concentration of these fragments, known as CYFRA 21.1, provides oncologists with a reliable biochemical indicator of tumour activity, cellular turnover, and therapeutic response, particularly in lung and bladder malignancies.
Lung Cancer Management
Evaluating this biomarker helps to:
- Monitor non-small cell lung cancer (NSCLC)
- Assess squamous cell carcinoma of the lung
- Complement pulmonary imaging scans
- Evaluate suspected lung masses
Urothelial Carcinoma
This test is highly useful because it:
- Supports bladder cancer diagnostics
- Assesses upper urinary tract tumours
- Monitors advanced urothelial disease
- Differentiates sources of haematuria
Therapeutic Tracking
The laboratory provides critical data to:
- Track response to chemotherapy
- Assess surgical clearance of tumours
- Detect post-remission recurrence early
- Guide ongoing oncological care plans
Clinical Uses
Why is Blood Testing for CYFRA 21.1 Important?
Imaging techniques like CT scans and MRIs are essential for locating and measuring the physical size of tumours, but they cannot always immediately determine if the tumour cells are actively dying in response to therapy. Serial testing of CYFRA 21.1 allows specialists to observe the biological behaviour of the cancer in real-time.
Tracking Active Treatment Response
During active oncology treatment (such as chemotherapy or radiotherapy), tracking CYFRA 21.1 is highly valuable:
- Confirming Efficacy: A rapid and sustained decrease in CYFRA 21.1 levels strongly correlates with tumour shrinkage and a positive response to therapy.
- Adjusting Protocols: If levels remain stubbornly high or begin to rise during treatment, it may indicate that the tumour is resistant to the current drugs, prompting a clinical review.
Post-Surgical & Long-Term Surveillance
Following surgical resection or successful remission, CYFRA 21.1 is integrated into follow-up care to:
- Confirm the completeness of surgical tumour removal (levels should normalize post-surgery).
- Act as an early warning system for disease recurrence. In many cases, a rising CYFRA 21.1 level can precede clinical symptoms or visible radiological changes by several months.
Understanding Lung Health & Oncology
A quantitative CYFRA 21.1 assay provides essential diagnostic evidence for respiratory physicians and oncologists. For further clinical guidance on identifying symptoms of lung conditions in the UK, consult the official NHS guide on lung cancer.
Clinic Excellence
Why Choose Medical Diagnosis Victoria (MDX Victoria)?
Specialist Referral Laboratory Analysis
Your blood sample is managed with strict pre-analytical controls and analysed at an accredited referral laboratory using validated automated immunoassay methods for precise biomarker tracking.
Reliable 5 Day Turnaround
Our logistics protocols ensure prompt sample transfer and analysis so your comprehensive pathology report is securely delivered within 5 days.
Central London Care
Conveniently situated in Victoria, our clinic provides a welcoming, discreet, and patient-focused environment for all your private diagnostic needs.
Clear Pricing
£90.00 test fee plus a £24.00 blood draw fee with no hidden costs. Our experienced practitioners ensure your visit is completely straightforward.
Pathology Reports
How To Read Your Laboratory Results
Your report will display your serum CYFRA 21.1 concentration in nanograms per millilitre (ng/mL). Normal reference ranges are generally low (typically < 3.3 ng/mL, depending on the specific assay used). Mild elevations can occur in benign respiratory diseases like COPD or pulmonary fibrosis. However, progressively rising or markedly high results strongly correlate with an active malignant process, particularly non-small cell lung cancer. Specialists interpret CYFRA 21.1 results by assessing the trend over multiple tests alongside radiological imaging.
Results Timeline: Your specialist diagnostic report is typically available within 5 days of your blood draw.
Medical Consultation
Need Help? Private GP Consultations
Tumour markers require experienced medical evaluation. If your CYFRA 21.1 result is elevated or shows an upward trend, or if you are troubled by persistent respiratory symptoms or urological issues, our private GP service is available on site. Our clinicians can interpret your results within your clinical context, arrange complementary blood tests (like CEA or SCC), and facilitate urgent referrals to consultant oncologists or respiratory physicians.
Clinic Support
Frequently Asked Questions
Do I need to fast before a CYFRA 21.1 blood test?
No special fasting is required before a CYFRA 21.1 blood test. You may eat and drink normally prior to your appointment.
What is CYFRA 21.1 primarily used for?
It is a specialised tumour marker most commonly used to monitor treatment response and detect the recurrence of non-small cell lung cancer (NSCLC) and urothelial (bladder) carcinoma.
Can benign conditions cause elevated CYFRA 21.1?
Yes. Mild to moderate elevations can sometimes occur in benign lung diseases such as chronic obstructive pulmonary disease (COPD), asthma, or severe pneumonia, as well as in certain liver or kidney conditions.
How quickly will I receive my CYFRA 21.1 test results?
Because this is a highly specialised oncology assay, your sample is sent to our accredited referral laboratory for precise immunoassay testing. Comprehensive results will be securely delivered within 5 days.
Is the phlebotomy fee included in the £90.00 price?
No, the £24.00 phlebotomy service fee is separate and covers the professional blood draw carried out by our qualified clinical practitioners at our central Victoria clinic.
Online Trends
Most Searched Online Questions About CYFRA 21.1
Is CYFRA 21.1 used for screening healthy people?
No, it is not sensitive or specific enough for population screening. It is strictly used to monitor patients already diagnosed with specific epithelial cancers. Using it as a general screening tool can lead to false alarms due to benign respiratory conditions.
What is the difference between small cell and non-small cell lung cancer?
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer (accounting for about 80-85% of cases) and arises from epithelial cells. CYFRA 21.1 is particularly sensitive for the squamous cell carcinoma subtype of NSCLC. Small cell lung cancer (SCLC) is a different, more aggressive type that uses different markers, such as NSE (Neuron-Specific Enolase).
Is this test used alongside other tumour markers?
Yes, oncologists frequently use CYFRA 21.1 in combination with other markers like CEA (Carcinoembryonic Antigen) or SCC (Squamous Cell Carcinoma antigen) to get a more comprehensive picture of the tumour’s biological activity.
Related Health Categories
Book Your Private Blood Test in London Today
Take Control of Your Oncology Follow-Up
Stay informed about your treatment progress and long-term recovery. Secure your CYFRA 21.1 (Cytokeratin-19 Fragments) blood test at Medical Diagnosis Victoria (MDX Victoria) today. Visit our welcoming, discreet London clinic and let our expert clinical team support your health journey with clear, accurate diagnostic monitoring.
Related Profiles/Tests
Cancer Related
Cancer Related
Anaemia
blood tests
blood tests
Cancer Related
Cancer Related
